Erbitux effective in cancer trial
Imclone announced that a late-stage trial shows that Erbitux combined with radiation therapy can prevent the spread of head and neck cancer. The drug proved statistically significant in both survival and progression-free survival among patients with head and neck cancer. The drug has already been approved for colorectal cancer.
"Head and neck cancer remains a disease with too few treatment options and no new therapeutic product approvals in over a decade," said Eric K. Rowinsky, chief medical officer of ImClone. "We look forward to discussing the next steps toward a regulatory filing with the FDA."
- read this story from the AP for more
ALSO: Wall Street financier Carl Icahn has indicated his intention to increase his stake in Imclone. He currently owns 6 percent of the company's stock.
More stories about FDA chief medical officer Drug Trials colorectal cancer head and neck cancer ImClone Erbitux
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
